bearish
Venus Medtech Lock-Up Expiry: Could Face Selling Pressure
397 Views11 Jun 2020 16:58
Venus Medtech is a dominant player in the heart valve replacement (TAVR) market in China and was listed in Hong Kong on December 10th. Since...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- MicroPort CardioFlow: PHIP Updates and More on TMV21 Jan 2021
- Venus Medtech (启明医疗) & Peijia Medical (沛嘉医疗) Placement - Take Your Pick21 Jan 2021
- Venus Medtech (启明医疗) Placement - Already Has Ample Cash but Doesn't Hurt to Have More for R&D02 Sep 2020
- Venus Medtech Lock-Up Expiry: Could Face Selling Pressure11 Jun 2020
- Venus Medtech (启明医疗) IPO Trading: Allocation and Buy-Level09 Dec 2019
- Venus Medtech (启明医疗) IPO: Valuation Still OK at the High End26 Nov 2019
x